[ad_1]
CONTEXT:
Proper management of depression is a priority for cancer treatment. However, many cancer survivors live with undiagnosed and untreated depression. Prostate cancer survivors may be particularly vulnerable, but their access to care for depression is poorly understood. The purpose of this study was to describe trends and predictors of clinical diagnosis and treatment of depression in prostate cancer survivors.
METHODS:
Generalized estimating equations were used to evaluate self-reported clinical diagnosis and depression indicators based on individual characteristics in a longitudinal dataset. The data came from a cohort based on the North Carolina prostate cancer survivor population enrolled between 2004 and 2007 on the North Carolina-Louisiana Prostate Cancer Project (N = 1,031). Treatment of prostate cancer in North Carolina (N = 805).
RESULTS:
The mean rate of self-reported clinical depression was 44% (95% CI: 39% to 49%), a 60% to 40% decrease between the diagnosis of prostate cancer and 5-7 years later. . Factors badociated with a lower probability of self-reported clinical depression include African-American race, employment, age at enrollment, low level of education, visits of infrequent primary care and the diagnosis of prostate cancer for more than 2 years. The average treatment rate for self-reported depression was 62% (95% CI: 55% to 69%). Factors badociated with a lower probability of self-reported depression treatment included employment and living with a diagnosis of prostate cancer for 2 years or more.
CONCLUSION:
Prostate cancer survivors face barriers when they need care for depression.
[ad_2]
Source link
